IMTX Immatics N.V.

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

$11.22  -0.46 (-3.94%)
As of 11/26/2021 13:00:01 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  
IPO date:  07/02/2020
Outstanding shares:  62,908,617
Average volume:  290,413
Market cap:   $734,772,647
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    N44445109
Valuation   (See tab for details)
PE ratio:   -7.12
PB ratio:   20.07
PS ratio:   23.02
Return on equity:   -270.76%
Net income %:   -334.26%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy